IL33 and melanoma: Studies of mouse models of melanoma have recently found that eosinophils recruited by ILC2 are associated with improved outcomes, and that boosting ILC function and eosinophil recruitment using combined anti-PD-1 and IL-33 induce anti-melanoma immunity.